Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML
Authors
Keywords
-
Journal
BLOOD
Volume 123, Issue 4, Pages 554-561
Publisher
American Society of Hematology
Online
2013-12-06
DOI
10.1182/blood-2013-09-527044
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical Significance of CD33 Nonsynonymous Single-Nucleotide Polymorphisms in Pediatric Patients with Acute Myeloid Leukemia Treated with Gemtuzumab-Ozogamicin-Containing Chemotherapy
- (2013) L. Mortland et al. CLINICAL CANCER RESEARCH
- Targeting T cells to tumor cells using bispecific antibodies
- (2013) Stanley R Frankel et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin
- (2013) Roland Walter Frontiers in Bioscience-Landmark
- Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy
- (2012) Guillermo Garcia-Manero BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance
- (2012) Karthika Natarajan et al. BIOCHEMICAL PHARMACOLOGY
- Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML
- (2012) J. A. Pollard et al. BLOOD
- Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
- (2012) M. S. Topp et al. BLOOD
- Acute myeloid leukemia stem cells and CD33-targeted immunotherapy
- (2012) R. B. Walter et al. BLOOD
- Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia
- (2012) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
- (2012) Sylvie Castaigne et al. LANCET
- T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct
- (2012) M Aigner et al. LEUKEMIA
- Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin
- (2012) M Kurimoto et al. LEUKEMIA
- Bispecific antibodies engage T cells for antitumor immunotherapy
- (2011) Bryan D Choi et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
- (2011) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
- (2010) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia
- (2010) A Quintás-Cardama et al. LEUKEMIA
- Bispecific T-Cell Engaging Antibodies for Cancer Therapy
- (2009) P. A. Baeuerle et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started